SOSV

Hoofprint Biome is a developer of probiotics that improve the sustainability of ruminant livestock production. Its probiotics and natural enzymes improve cattle health and digestive care by eliminating methane and enabling the livestock industry to catalyze the symbiotic agriculture movement with microbiome engineering.

InnSight Technology is a biotechnology company focused on enhancing diagnostics and evaluation of eye diseases. The company develops innovative ophthalmic devices, including a novel hand-held biosensor designed for the detection of anterior ophthalmic injuries. Additionally, InnSight Technology works on advanced nanotechnology-based medical devices aimed at addressing specific clinical needs in ophthalmology. By providing these tools, the company seeks to improve ocular care for clinicians and their patients.

Sharper Sense is a company focused on wearable neurotechnology designed to enhance sensory acuity, including vision, hearing, and touch. The firm has developed a neuromodulation patch that employs comfortable, noninvasive electrical stimulation to improve sensory processing. This technology has both clinical and commercial applications, particularly in treating sensory processing disorders and sensory loss. By enhancing performance and safety, Sharper Sense aims to provide users with a clearer and more accurate perception of their surroundings.

Hoofprint Biome is a developer of probiotics that improve the sustainability of ruminant livestock production. Its probiotics and natural enzymes improve cattle health and digestive care by eliminating methane and enabling the livestock industry to catalyze the symbiotic agriculture movement with microbiome engineering.

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

Ostoform is a spin-out medical device company from the University of Limerick, Ireland with a range of patented technologies, and the potential to scale, becoming a global leader in the area of ostomy skin health.

Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to detect and eliminate cancer from within the body. The company is dedicated to advancing scientific breakthroughs that lead to new classes of treatments, providing significant improvements in medicine. RyboDyn's work is particularly concentrated on creating upgraded therapies for serious diseases, including terminal conditions, with the goal of enhancing patient outcomes and expanding treatment options.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Serene Sleep specializes in developing treatment procedures for snoring and sleep apnea using palatal implants.

Seismi is a veterinary healthcare company that provides vitals monitoring, cattle sensor, methane emission analytics solutions.

Ten63 Therapeutics is a biotechnology company focused on developing innovative therapeutics for challenging diseases, particularly those involving targets previously considered undruggable. Founded in 2017 and based in Chapel Hill, North Carolina, the company utilizes its proprietary platform, COPPER, which integrates advanced artificial intelligence and state-of-the-art physical models to explore vast chemical spaces. By employing low-residual, machine learning-based computational chemistry alongside superlinear search algorithms, Ten63 Therapeutics aims to identify and optimize drug candidates effectively. Their approach includes proprietary scaffold redesign and hopping technology, enabling the screening of trillions of molecules to predict resistance and redesign antibodies. This combination of techniques positions Ten63 Therapeutics at the forefront of developing durable treatments for some of the most lethal diseases.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

BioLattice addresses the need for tissue healing solutions.

Vitarka Therapeutics develops medical technology and solutions for various types of cancer. It is based in London, United Kingdom.

Medical Devices, Kidney Disease, Wearables, Medtech, Hardtech

VIAN Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop intended to replace traditional injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical trials, VIAN aims to meet significant unmet medical needs in the retinal disease market, which is valued at $15 billion. Additionally, the company is engaged in the creation of peptide drugs that enhance efficacy and safety for treating both ophthalmic and oncology-related conditions by targeting angiogenesis, thereby offering patients improved health outcomes.

Laguna Bio provides a drug discovery platform designed that activates and expands the innate immune system against cancer. It focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of a bispecific antibody drug. Laguna Biotherapeutics was founded in 2022 and is headquartered in Berkeley, California.

FREZENT is a biotechnology company that develops novel therapeutics for advanced-stage cancer patients.

Metabolic Psychiatry Labs is a mental healthcare company offering assessments, lab tests, and wellness solutions based on metabolic therapy.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Minutia is focused on developing innovative solutions for Type 1 Diabetes through stem cell-derived transplants that incorporate nanosensors. The company specializes in creating subcutaneous insulin-producing cell transplants that are immune-evasive and capable of real-time monitoring via proprietary cell-based sensors. This approach aims to address common challenges associated with transplants and seeks to provide a functional cure for diabetes. By advancing both transplantation techniques and monitoring capabilities, Minutia aspires to transform the clinical landscape of diabetes management and cell replacement therapies.

Asta Bio is the developer of radiotherapeutics intended for cancer patients and offers technology by combining 211-Astatine.

Tinkeso Therapeutics is a biotechnology company that provides cell therapeutics solutions to cure cancer and autoimmune disorders.

heXem bio specializes in recording solutions for the early development of humans for longevity.

Zhenshi Medical is a medical device company that specializes in lung puncture medical robots for diagnosing and treating lung cancer.

CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation

DeepSpin GmbH, founded in 2019 and based in Berlin, Germany, specializes in developing artificial intelligence-powered magnetic resonance imaging (MRI) equipment. The company’s innovative technology aims to provide MRI imaging systems that are significantly smaller, lighter, and more cost-effective than traditional models. By leveraging generative topological design and deep learning techniques, DeepSpin's MRI machines enhance accessibility to medical imaging, making it available to a wider range of patients globally. This approach seeks to improve healthcare standards in various medical fields previously lacking adequate imaging solutions.

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Kegg is a fertility tracking device that combines the functions of monitoring vaginal fluid and facilitating pelvic floor exercises. Founded in 2017 and based in San Francisco, California, Kegg utilizes advanced sensing technology to detect changes in cervical fluid, thereby enabling women to identify their fertile window and ovulation up to seven days in advance. This innovative approach provides essential data that enhances the diagnosis, monitoring, and treatment of women's reproductive health, significantly increasing the chances of natural conception. By offering an intuitive and effective solution, Kegg empowers women with the information they need to make informed decisions regarding their fertility.

VIAN Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop intended to replace traditional injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical trials, VIAN aims to meet significant unmet medical needs in the retinal disease market, which is valued at $15 billion. Additionally, the company is engaged in the creation of peptide drugs that enhance efficacy and safety for treating both ophthalmic and oncology-related conditions by targeting angiogenesis, thereby offering patients improved health outcomes.

OncoPrecision is a company that focuses on improving cancer therapy outcomes by utilizing a patient micro avatar platform. This innovative platform employs single-cell high-throughput biology and machine learning to generate comprehensive patient-derived phenotypic biomarkers. By doing so, it enables oncologists to make informed, data-driven decisions regarding the selection of cancer therapies tailored to individual patients. The approach aims to increase the success rates of cancer treatments by ensuring that the right therapy is matched to the right patient, thus enhancing overall patient care and treatment effectiveness.

GlowDx is a diagnostics company based in Midleton, Ireland, established in 2015. The company focuses on decentralizing molecular testing through innovative point-of-care technologies, which facilitate local access to diagnostics for tropical diseases. By combining novel molecular technology with effective delivery models, GlowDx aims to improve clinical outcomes while reducing the economic burden on patients and healthcare systems. This approach enhances the quality of life for individuals by ensuring they receive timely and accurate diagnostic information, thereby enabling healthcare providers to offer better-targeted treatments.

FeetMe is a digital health company specializing in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative wearable products, particularly smart insoles equipped with pressure sensors and motion analysis algorithms. These products enable real-time monitoring of patients' mobility and posture, facilitating comprehensive evaluations of movement disorders and mobility constraints. By providing relevant digital biomarkers, FeetMe aims to support clinical research and enhance patient care, allowing healthcare professionals to track disease progression, improve functional outcomes, and optimize treatment strategies.

VisusNano Ltd. is a privately held pre-clinical company developing a drug-eluting intraocular lens implant, for use in patients undergoing cataract surgery. By improving patient outcomes, obviating the need for eye drops after surgery, and avoiding the need for laser treatment after surgery, our project has the potential to revolutionise cataract surgery in both the human and veterinary markets.

Lief Therapeutics is a medical device company focused on improving at-home care for individuals suffering from post-traumatic stress disorder, depression, and anxiety. The company has developed a discreet biosensing patch that measures heart rate and breathing patterns with medical accuracy. This wearable device, known as Lief, helps users manage their stress responses through biofeedback exercises, allowing them to monitor their emotions and behaviors in real-time. Additionally, the device provides clinicians with insights into patient progress, enabling in-session training and tracking of psychological assessments. Lief Therapeutics also offers the Lief Health Score application, which records thoughts, emotions, and sensations, facilitating the tracking of daily progress and personalized practice exercises. Founded in 2014 and based in San Francisco, California, the company sells its products online.

CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation

EasyAspataal provides a tech-enabled platform that connects patients and hospitals with multiple stakeholders.

Developing increasingly challenging vaccine targets requires increasingly sophisticated technologies. Over the last century, vaccines have made essential contributions to the doubling of human life expectancy. Calder engineers next-generation vaccines that will further protect against the most intractable and life-threatening viruses. Viruses have evolved to become shapeshifters that can evade and distract our immune system by hiding some of their most vulnerable sites. History has shown that pandemics are not only lethal but also inevitable. Currently, the vaccines we know best poorly protect against pandemics and other viral outbreaks and leave many at-risk populations unprotected. By combining structure-based design as part of a novel manufacturing process, Calder’s unique 3D-Vaxlock technology generates molecular staples that lock vaccines into their most potent shape. Their initial focus is on generating a universal flu vaccine that protects against all seasonal strains and an RSV vaccine specifically for the elderly. With this platform, they have the ability to create treatments that better protect against life-threatening diseases with exceptional safety, efficacy, and durability. Calder’s next generation vaccines will prevent severe disease and deaths, alleviate a substantial burden on the healthcare system, and allow billions of people to lead healthy lives.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to detect and eliminate cancer from within the body. The company is dedicated to advancing scientific breakthroughs that lead to new classes of treatments, providing significant improvements in medicine. RyboDyn's work is particularly concentrated on creating upgraded therapies for serious diseases, including terminal conditions, with the goal of enhancing patient outcomes and expanding treatment options.

Hypercell Technologies develops tools to control infectious diseases in animals. Hypercell believes that the best chance to stop a future pandemic in humans is to prevent it by proactively controlling viruses in production animal reservoirs.

FluidAI Medical is a company dedicated to enhancing patient care through innovative technology in post-operative recovery. It has developed a smart catheter system that employs artificial intelligence to monitor patients' health data within the body. This proactive approach enables the early detection of postoperative complications, allowing healthcare providers to access critical health information promptly. By leveraging data-driven insights, FluidAI aims to improve recovery outcomes and transform the standards of post-operative care.

Optimize Health is a digital healthcare provider specializing in remote patient monitoring (RPM) solutions. The company offers a user-friendly platform that incorporates both equipment and software designed to streamline the implementation of RPM programs. Its software aids healthcare providers in complying with Medicare billing requirements for RPM services while ensuring a positive experience for both patients and providers. The platform automatically tracks medication doses and sends reminders to users, leveraging Bluetooth technology to sync with smartphones and tablets. This approach empowers patients to manage their health effectively and enables physicians to achieve profitability from RPM services starting in the first month.

Rizlab Health enables practitioners and patients to acquire full blood count readings in minutes. Founded in 2018 and is based in East Princeton.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

FREZENT is a biotechnology company that develops novel therapeutics for advanced-stage cancer patients.

Medical Devices, Kidney Disease, Wearables, Medtech, Hardtech

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Developing increasingly challenging vaccine targets requires increasingly sophisticated technologies. Over the last century, vaccines have made essential contributions to the doubling of human life expectancy. Calder engineers next-generation vaccines that will further protect against the most intractable and life-threatening viruses. Viruses have evolved to become shapeshifters that can evade and distract our immune system by hiding some of their most vulnerable sites. History has shown that pandemics are not only lethal but also inevitable. Currently, the vaccines we know best poorly protect against pandemics and other viral outbreaks and leave many at-risk populations unprotected. By combining structure-based design as part of a novel manufacturing process, Calder’s unique 3D-Vaxlock technology generates molecular staples that lock vaccines into their most potent shape. Their initial focus is on generating a universal flu vaccine that protects against all seasonal strains and an RSV vaccine specifically for the elderly. With this platform, they have the ability to create treatments that better protect against life-threatening diseases with exceptional safety, efficacy, and durability. Calder’s next generation vaccines will prevent severe disease and deaths, alleviate a substantial burden on the healthcare system, and allow billions of people to lead healthy lives.

MedIQ is an integrated virtual care platform providing on-demand healthcare at the point of need. MedIQ redefines healthcare through a digitally enabled, cashless, hybrid healthcare ecosystem. MedIQ makes high-quality, modernized healthcare and wellness available to everyone.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation

VIAN Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop intended to replace traditional injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical trials, VIAN aims to meet significant unmet medical needs in the retinal disease market, which is valued at $15 billion. Additionally, the company is engaged in the creation of peptide drugs that enhance efficacy and safety for treating both ophthalmic and oncology-related conditions by targeting angiogenesis, thereby offering patients improved health outcomes.

Optimize Health is a digital healthcare provider specializing in remote patient monitoring (RPM) solutions. The company offers a user-friendly platform that incorporates both equipment and software designed to streamline the implementation of RPM programs. Its software aids healthcare providers in complying with Medicare billing requirements for RPM services while ensuring a positive experience for both patients and providers. The platform automatically tracks medication doses and sends reminders to users, leveraging Bluetooth technology to sync with smartphones and tablets. This approach empowers patients to manage their health effectively and enables physicians to achieve profitability from RPM services starting in the first month.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

Leadoptik is a deep-tech company focused on developing advanced miniature imaging technology designed for minimally invasive medical procedures. Its platform enhances surgical capabilities by providing high-resolution imaging and 3D navigation in real time, allowing surgeons to visualize small anatomical structures with greater clarity than existing imaging systems. This innovative approach facilitates the early detection of cancer and improves the overall effectiveness of surgical interventions, ultimately contributing to better patient outcomes.

AvantGuard creats innovative solutions that manage surfaces and provide long-term protection against viruses, bacteria, and fungi/mold, in a variety of applications.

Kresko RNAtech is a biotechnology company focused on the development and production of nutraceuticals. The company specializes in identifying bioactive ribonucleic acid (RNA) from natural sources, utilizing advanced techniques such as machine learning and bioinformatics. By uncovering RNAs that may offer health benefits, Kresko RNAtech aims to enhance human well-being and help individuals manage stressful and changing conditions through innovative RNA technologies.

Ten63 Therapeutics is a biotechnology company focused on developing innovative therapeutics for challenging diseases, particularly those involving targets previously considered undruggable. Founded in 2017 and based in Chapel Hill, North Carolina, the company utilizes its proprietary platform, COPPER, which integrates advanced artificial intelligence and state-of-the-art physical models to explore vast chemical spaces. By employing low-residual, machine learning-based computational chemistry alongside superlinear search algorithms, Ten63 Therapeutics aims to identify and optimize drug candidates effectively. Their approach includes proprietary scaffold redesign and hopping technology, enabling the screening of trillions of molecules to predict resistance and redesign antibodies. This combination of techniques positions Ten63 Therapeutics at the forefront of developing durable treatments for some of the most lethal diseases.

Vitarka Therapeutics develops medical technology and solutions for various types of cancer. It is based in London, United Kingdom.

AuraSense is focused on enhancing neurological assessments through the integration of artificial intelligence and automation. The company has developed a digital touch technology that enables the detection of early signs of limb damage, facilitating remote physical examinations for various diseases. By combining elements of video game technology with practical medical procedures, AuraSense provides neurologists with a data-driven and quantifiable approach to evaluate patients' cognitive and physical health. This innovation allows for accurate performance assessments, leading to personalized treatment plans tailored to individual patient needs, ultimately aiming to improve health outcomes.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

Japet Medical Devices is a French biomedical company focused on developing innovative robotic equipment aimed at enhancing treatment quality. The company specializes in wearable robotic exoskeletons that integrate medical and robotic technologies to assist with both occupational and daily health needs. These exoskeletons are designed to restore balance and facilitate free movement, offering pain relief through orthotic support. Japet's commitment to creating user-friendly solutions reflects its belief in the transformative potential of these technologies to improve the quality of life for many individuals.

VisusNano Ltd. is a privately held pre-clinical company developing a drug-eluting intraocular lens implant, for use in patients undergoing cataract surgery. By improving patient outcomes, obviating the need for eye drops after surgery, and avoiding the need for laser treatment after surgery, our project has the potential to revolutionise cataract surgery in both the human and veterinary markets.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Midoconline is a technology company that specializes in providing medical and wellness services aimed at enhancing quality of life. The company has developed a telehealth platform that facilitates video-based consultations between patients and doctors. Through a mobile application, patients can easily connect with healthcare professionals to receive remote consultations for non-emergency medical issues, thereby improving access to healthcare services.

Lief Therapeutics is a medical device company focused on improving at-home care for individuals suffering from post-traumatic stress disorder, depression, and anxiety. The company has developed a discreet biosensing patch that measures heart rate and breathing patterns with medical accuracy. This wearable device, known as Lief, helps users manage their stress responses through biofeedback exercises, allowing them to monitor their emotions and behaviors in real-time. Additionally, the device provides clinicians with insights into patient progress, enabling in-session training and tracking of psychological assessments. Lief Therapeutics also offers the Lief Health Score application, which records thoughts, emotions, and sensations, facilitating the tracking of daily progress and personalized practice exercises. Founded in 2014 and based in San Francisco, California, the company sells its products online.

Aluna is focused on empowering patients with chronic respiratory conditions, particularly asthma, by providing tools for better understanding and management of their lung health. The company has developed a portable spirometer device that utilizes machine learning and integrates with a mobile app. This technology allows patients to take daily measurements of their asthma, track symptoms, medication use, exercise, and environmental factors. By objectively monitoring asthma severity, the device enables healthcare providers to detect early signs of asthma attacks and create personalized, real-time action plans for their patients. Aluna is committed to enhancing the quality of life for individuals with asthma through innovative medical devices and healthcare solutions.

AvantGuard creats innovative solutions that manage surfaces and provide long-term protection against viruses, bacteria, and fungi/mold, in a variety of applications.

BioROSA Technologies Inc. is a Belmont, Massachusetts-based company focused on developing blood tests for Autism Spectrum Disorders (ASD). Founded in 2018, the company aims to establish a biologically-based standard of care for ASD through innovative diagnostic tools. These tools enable clinicians to identify individuals at risk for ASD by utilizing blood-based biomarkers and advanced machine learning techniques. BioROSA’s platform not only enhances early detection and diagnosis but also supports therapeutic developments by facilitating patient stratification and assessing pharmacodynamics in clinical trials. This comprehensive approach equips healthcare professionals with the necessary resources to improve patient outcomes through timely intervention.

Bisu is a health technology company that offers a home health lab designed to enhance personal well-being through urine and saliva tests. Its devices monitor various health metrics, including dietary health, fat metabolism, and hydration levels, providing users with daily feedback on electrolytes, hydration, pH, ketones, and uric acid via a mobile application. This functionality enables individuals to track burned body fat, maintain metabolic health, achieve optimal ketosis, and improve physical endurance. Bisu has received recognition for its innovation, having been awarded by prestigious organizations such as Johnson & Johnson Innovation and MedTech Innovator, and it gained further acclaim at CES 2020 with the IHS Markit Innovation Award.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Vitarka Therapeutics develops medical technology and solutions for various types of cancer. It is based in London, United Kingdom.

ClearDekho is an online eyewear marketplace based in Uttar Pradesh, specializing in a diverse selection of eyewear products. The company offers prescription eyeglasses, sunglasses, reading glasses, computer glasses, and branded contact lenses. It provides customers with the convenience of purchasing eyewear through both online and offline channels, ensuring affordability and accessibility. ClearDekho aims to meet the growing demand for quality eyewear while catering to a wide range of customer needs.

Aima offers a weekly proactive pain management system to menstruators to manage pain. Aima was founded in 2019 and was headquartered in Vancouver, Canada.

EasyAspataal provides a tech-enabled platform that connects patients and hospitals with multiple stakeholders.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Laguna Bio provides a drug discovery platform designed that activates and expands the innate immune system against cancer. It focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of a bispecific antibody drug. Laguna Biotherapeutics was founded in 2022 and is headquartered in Berkeley, California.

RxDiet is a developer of a nutritional guidance platform that leverages artificial intelligence and automation to provide personalized meal solutions and health interventions. The company partners with national food retailers and leading health plans to deliver fresh groceries tailored to individual cultural and lifestyle preferences. This approach not only promotes a balanced diet but also aims to achieve exceptional clinical outcomes and cost savings for users. By integrating "food as medicine" principles, RxDiet addresses the growing demand for effective nutritional support in healthcare.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Prospective Research, Inc. is a biotechnology company based in Beverly, Massachusetts, focused on developing innovative solutions for the aquaculture industry and antibiotic discovery. Established in 2015, the company utilizes its advanced technology platforms, including MicrobeMiner and GeneMiner, to access untapped antibiotics from soil-dwelling microbes. By employing microbial signaling molecules, Prospective Research creates feed incorporated preventative disease management solutions that eliminate the need for traditional antibiotics and medicated feed. Their approach involves modulating bacterial behavior and introducing trillions of beneficial bacteria into the microbiomes of farmed species such as fin-fish, shrimp, and shellfish. This technology enables the selective activation of genes that produce bio-active therapeutics, offering protection against various pathogens while enhancing the health of aquaculture species.

GlowDx is a diagnostics company based in Midleton, Ireland, established in 2015. The company focuses on decentralizing molecular testing through innovative point-of-care technologies, which facilitate local access to diagnostics for tropical diseases. By combining novel molecular technology with effective delivery models, GlowDx aims to improve clinical outcomes while reducing the economic burden on patients and healthcare systems. This approach enhances the quality of life for individuals by ensuring they receive timely and accurate diagnostic information, thereby enabling healthcare providers to offer better-targeted treatments.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

BioLumen is a nutritional technology company that develops a patented dietary fiber technology platform that reduces the negative effect of a diet heavy in processed foods. BioLumen's technology is composed of insoluble dietary fiber matrix covered with a blend of food ingredients created from the latest drug delivery system research. The company's product, a nutraceutical, focuses on high risk individuals with prediabetes to help manage blood sugar levels, protect their liver from excess sugar and feed their gut microbiome, delivering health benefits. BioLumen was founded on 2018 and is headquartered in San Francisco, California.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Kinexcs is an AI-driven health platform and wearables company focused on enhancing mobility and improving quality of life for individuals with musculoskeletal conditions. It addresses issues of incomplete recovery and patient compliance through its innovative digital therapy solutions, which are both cost-effective and convenient. The company has developed KIMIA, the world's first continuous knee health monitor, combined with an AI-based digital therapist that facilitates access to therapy. Kinexcs collaborates with key opinion leaders and major public hospitals in Singapore on various clinical projects, while also offering its products through orthopedic surgeons and significant implant manufacturers. The integration of continuous monitoring and real-time exercise guidance supports patients in managing their conditions effectively.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

FluidAI Medical is a company dedicated to enhancing patient care through innovative technology in post-operative recovery. It has developed a smart catheter system that employs artificial intelligence to monitor patients' health data within the body. This proactive approach enables the early detection of postoperative complications, allowing healthcare providers to access critical health information promptly. By leveraging data-driven insights, FluidAI aims to improve recovery outcomes and transform the standards of post-operative care.

Aksense is a biotechnology company focused on developing affordable and portable nucleic acid-based diagnostic panels for the rapid and accurate detection of pathogens. The company has created a portable rapid infection diagnostic biosensor designed to enhance healthcare by providing high-quality and safe care. Aksense's technology aims to improve antibiotic prescribing practices and public health outcomes by enabling early detection and treatment of infections. This approach reduces the spread of infections and improves patient outcomes, allowing users to achieve faster recovery through cost-effective molecular testing solutions.